Table 1 .
Comparison of baseline clinical, oncological, CMR, and blood biomarker characteristics of the patients in the statin and placebo groups
| Statin N = 54 | Placebo N = 58 | |
|---|---|---|
| Age, years | 55.2 (13.7) | 58.6 (13.4) |
| ≥60 years, n(%) | 25 (46%) | 31 (53%) |
| Female sex n (%) | 39 (72%) | 48 (83%) |
| Race, n (%)* | ||
| White | 36 (67%) | 46 (79%) |
| Black | 2 (4%) | 2 (3%) |
| Non black Hispanic | 2 (4%) | 0 (0%) |
| Asian | 13 (24%) | 9 (16%) |
| Other | 1 (2%) | 1 (2%) |
| Systolic blood pressure, mmHg | 132 (20) | 126 (16) |
| Diastolic blood pressure, mmHg | 80 (11) | 79 (9) |
| Heart rate, bpm | 78 (15) | 76 (11) |
| Diabetes, n (%) | 3 (6%) | 4 (7%) |
| Hypertension, n (%) | 11 (20%) | 18 (31%) |
| Dyslipidemia, n (%) | 2 (4%) | 3 (5%) |
| Smoking, n (%) | 25 (46%) | 26 (45%) |
| Baseline medications, n (%) | ||
| ACE inhibitor | 3 (6%) | 6 (10%) |
| Angiotensin receptor blocker | 3 (6%) | 4 (7%) |
| Betablocker | 3 (6%) | 2 (3%) |
| MRA | 1 (2%) | 1 (2%) |
| Any cardiac medication | 7 (13%) | 7 (12%) |
| Breast Cancer, n (%) | 35 (65%) | 38 (66%) |
| Breast Cancer stage, n (%) | ||
| 1 | 5 (14%) | 4 (11%) |
| 2 | 23 (66%) | 23 (61%) |
| 3 | 7 (20%) | 11 (29%) |
| Breast cancer side, n (%) | ||
| Left | 18 (51%) | 17 (45%) |
| Right | 15 (43%) | 20 (53%) |
| Bilateral | 2 (6%) | 1 (3%) |
| Lymphoma, n (%) | 12 (23%) | 12 (21%) |
| Leukemia, n (%) | 1 (2%) | 2 (3%) |
| Sarcoma, n (%) | 3 (6%) | 4 (7%) |
| Thymoma, n (%) | 3 (6%) | 2 (3%) |
| High CTRCD risk criteria* | ||
| Criterion #1 | 20 (37%) | 25 (43%) |
| Criterion #2 | 17 (31%) | 16 (28%) |
| Criterion #3 | 17 (31%) | 17 (29%) |
*Note these are mutually exclusive and represent the primary criteria used in recruitment (some patients may meet more than one high CTRCD risk criteria). All continuous data are presented as mean (SD), or median (IQR), all categorical data are presented as N (%), which represents the number of patients (percentage). ACE, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blocker; MRA, mineralocorticoid receptor antagonist.